Birhiray, R. E. Et Al. 2024. Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).. Special Clinical Science Symposia , (ELECTR NETWORK).

Birhiray, R. E., Luminari, S., Kim, T. M., Yagci, M., Wassenaar, T. R., Risal, A., ... Namuduri, M.(2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1). . Special Clinical Science Symposia, ELECTR NETWORK

Birhiray, Ruemu Et Al. "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).," Special Clinical Science Symposia, ELECTR NETWORK, 2024

Birhiray, Ruemu E. Et Al. "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).." Special Clinical Science Symposia , ELECTR NETWORK, 2024

Birhiray, R. E. Et Al. (2024) . "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).." Special Clinical Science Symposia , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={Ruemu Ejedafeta Birhiray Et Al. }, title={Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1).}, congress name={Special Clinical Science Symposia}, city={}, country={ELECTR NETWORK}, year={2024}}